- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| HEARTBEAM Aktie jetzt für 0€ handeln | |||||
| 12.12.25 | Heartbeam stock is a buy, this analyst says | 2 | Cantech Letter | ||
| 11.12.25 | HeartBeam-Aktie schießt nach FDA-Zulassung in die Höhe - H.C. Wainwright verdoppelt Kursziel | 7 | Investing.com Deutsch | ||
| 11.12.25 | HeartBeam stock soars as H.C. Wainwright doubles price target on FDA clearance | 4 | Investing.com | ||
| 10.12.25 | Why Is Micro Cap HeartBeam Stock Surging On Wednesday? | 1 | Benzinga.com | ||
| 10.12.25 | HeartBeam-Aktie steigt nach FDA-Zulassung für 12-Kanal-EKG-Software sprunghaft an | 10 | Investing.com Deutsch | ||
| 10.12.25 | HeartBeam Granted FDA Clearance For First Cable-Free 12-Lead ECG For At-Home Assessment | 1 | RTTNews | ||
| 10.12.25 | HeartBeam earns FDA clearance for first-ever cable-free 12-lead ECG for at-home arrhythmia assessment | 1 | MassDevice | ||
| 10.12.25 | HeartBeam's 12-lead ECG synthesis software receives FDA clearance | 1 | Investing.com | ||
| 27.11.25 | What's Behind HeartBeam's Over 40% After-Hours Surge? | 4 | Benzinga.com | ||
| 26.11.25 | HeartBeam-Aktie legt zu: FDA signalisiert nach Rückschlag Weg für EKG-Software | 10 | Investing.com Deutsch | ||
| 26.11.25 | Nach FDA-Rückschlag: HeartBeam prüft mehrere Optionen für EKG-Software | 1 | Investing.com Deutsch | ||
| 26.11.25 | HeartBeam pursues multiple options after FDA rejection of ECG software | 2 | Investing.com | ||
| 21.11.25 | HeartBeam erleidet Rückschlag: FDA verweigert Gleichwertigkeits-Status für EKG-Software | 4 | Investing.com Deutsch | ||
| 21.11.25 | HeartBeam, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.11.25 | HeartBeam stock maintains Speculative Buy rating at Benchmark on upcoming FDA clearance | 2 | Investing.com | ||
| 12.11.25 | HeartBeam Earnings Preview | 1 | Benzinga.com | ||
| 31.10.25 | Roth/MKM startet Coverage für Heartbeam mit Kaufempfehlung - Kurspotenzial von 148 % gesehen | 4 | Investing.com Deutsch | ||
| 31.10.25 | Heartbeam stock initiated with Buy rating at Roth/MKM on cardiac device potential | 1 | Investing.com | ||
| 08.09.25 | HeartBeam's AI algorithm shows equal performance on 3D and standard ECGs | 1 | Investing.com | ||
| 13.08.25 | HeartBeam Q2 2025 slides: FDA clearance on track amid improved capital efficiency | 1 | Investing.com |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 15,180 | +0,86 % | Abend-Update: Eckert&Ziegler-Aktie verliert deutlich - bricht jetzt das Vertrauen weg? | ||
| ATOSSA THERAPEUTICS | 0,560 | +5,46 % | Atossa Therapeutics Inc: Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy | Designation expands (Z)-Endoxifen program into rare pediatric neuromuscular disease and may qualify Atossa for a future Priority Review Voucher upon approval
SEATTLE... ► Artikel lesen | |
| CATHETER PRECISION | 2,050 | 0,00 % | Catheter Precision, Inc.: Historic Win for Electrophysiology Reimbursement in Ambulatory Surgery Centers Provides Unique Opportunity for Catheter Precision's LockeT Device | FORT MILL, S.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the... ► Artikel lesen | |
| INTELLIGENT BIO SOLUTIONS | 11,000 | 0,00 % | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Announces New Manufacturing Partnership to Strengthen Global Production Capability and Increase Margins | NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 21,020 | +3,96 % | Alignment Healthcare Reports Third Quarter 2025 Results, Surpasses High-End of Guidance Across All Key Metrics | Reports Q3 revenue of $993.7 million, up 43.5% year-over-yearBeats high end of third quarter guidance and raises full-year outlook across all key metrics: membership, revenue, adjusted gross profit... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 39,260 | +2,24 % | S&P Dow Jones Indices: BrightSpring Health Services Set to Join S&P SmallCap 600 | NEW YORK, Oct. 14, 2025 /PRNewswire/ -- BrightSpring Health Services Inc. (NASD: BTSG) will replace Veritex Holdings Inc. (NASD: VBTX) in the S&P SmallCap 600 effective... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 33,130 | +7,70 % | PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance | SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 45,630 | +1,63 % | JEFFERIES stuft Siemens Healthineers auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Siemens Healthineers vor Zahlen zum ersten Geschäftsquartal auf "Buy" mit einem Kursziel von 60 Euro belassen. Der Medizintechnikkonzern... ► Artikel lesen | |
| BETA BIONICS | 29,570 | +1,09 % | Beta Bionics, Inc.: Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance | IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen | |
| PROGYNY | 26,645 | +3,52 % | Progyny, Inc. Announces Third Quarter 2025 Results | Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and... ► Artikel lesen | |
| CERIBELL | 20,810 | 0,00 % | Protara, CeriBell rise on FDA breakthrough designations | ||
| AVEANNA HEALTHCARE | 8,220 | +1,61 % | Aveanna Healthcare Holdings, Inc: Aveanna Healthcare Holdings Announces Third Quarter Financial Results and Revised 2025 Outlook | Third Quarter Revenue was $621.9 million, a 22.2% increase over the prior year periodThird Quarter Net income was $14.1 million compared to Net loss of $42.8 million for the prior year periodAdjusted... ► Artikel lesen | |
| PACS GROUP | 39,720 | +0,51 % | Morning Market Movers: Mobile-health Network Solutions, PACS Group, Brera Holdings, Cerence See Big Swings | SANTA CLARA (dpa-AFX) - At 7:55 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ADAPTHEALTH | 9,780 | +1,14 % | AdaptHealth: Strategische Expansion und Technologie-Investitionen als Wachstumstreiber | ||
| GENEDX | 131,41 | -0,67 % | GeneDx to Participate in Upcoming Investor Conferences | GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:
Stifel... ► Artikel lesen |
HEARTBEAM INC gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 2,735 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HEARTBEAM INC finden Sie auf Wallstreet Online.